157 related articles for article (PubMed ID: 31471582)
1. Nothing to gain for p53.
Harjes U
Nat Rev Cancer; 2019 Oct; 19(10):544-545. PubMed ID: 31471582
[No Abstract] [Full Text] [Related]
2. Emerging Non-Canonical Functions and Regulation of p53.
Ranjan A; Iwakuma T
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29597309
[TBL] [Abstract][Full Text] [Related]
3. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 gain-of-function in cancer.
Oren M; Rotter V
Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
[TBL] [Abstract][Full Text] [Related]
6. p53 gain-of-function: tumor biology and bioinformatics come together.
Koonin EV; Rogozin IB; Glazko GV
Cell Cycle; 2005 May; 4(5):686-8. PubMed ID: 15846083
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations promote proteasomal activity.
Oren M; Kotler E
Nat Cell Biol; 2016 Jul; 18(8):833-5. PubMed ID: 27463250
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic roles of p53 mutants in mouse models.
Lozano G
Curr Opin Genet Dev; 2007 Feb; 17(1):66-70. PubMed ID: 17208429
[TBL] [Abstract][Full Text] [Related]
9. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
10. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
11. Cancer biology: sense out of missense.
Van Dyke T
Nature; 2005 Mar; 434(7031):287-8. PubMed ID: 15772635
[No Abstract] [Full Text] [Related]
12. Recent advances in p53 research: an interdisciplinary perspective.
Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
[TBL] [Abstract][Full Text] [Related]
13. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
14. p53 Mutants Access Epigenetic Pathways to Promote Tumor Growth.
Cancer Discov; 2015 Nov; 5(11):OF2. PubMed ID: 26424413
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
16. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
17. Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells.
Horiuchi H; Kawamata H; Omotehara F; Fujii S; Fujimori T; Kuroda Y
J Gastroenterol; 2004 Aug; 39(8):801-3. PubMed ID: 15338377
[No Abstract] [Full Text] [Related]
18. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.
Rollenhagen C; Chène P
Int J Cancer; 1998 Oct; 78(3):372-6. PubMed ID: 9766574
[TBL] [Abstract][Full Text] [Related]
19. Disrupting TP53 in mouse models of human cancers.
Parant JM; Lozano G
Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
